Evaluation on the safety and efficacy of tirofiban in patients with acute myocardial infarction treated by primary percutaneous coronary intervention

Objective Evaluation on the safety and efficacy of Tirofiban in patients with acute myocar-dial infarction(AMI) treated by primary percutaneous coronary intervention (PCI). Methods 150 consecutive patients with AMI were observed form 2007 to 2008. All the individuals were performed PCI within 12 hours af-ter onset of AMI. 150 cases were divided into two groups:the control group (n = 72), the test group (n = 78)re-ceived the same treatment as group plus Tirofiban. Thrombolysis in acute myocardial infarction(TIMI) grade was observed. The major adverse cardiac events (MACE) at 4 weeks and bleeding complications were studied. Re-suits All the individuals of both group had no the MACE. In the test group, the occurance of slow-reflow at 4 weeks were lower than those in control group, there was significant difference in both groups. 24 cases of oc-curred adverse reaction in test group (30. 8%), 18 cases of occurred adverse reaction in control group (25.7%) ,there was no significant difference. Conclusion Application of Tirofiban during primary PCI in pa-tients with AMI was safe and effective, which may improve TIMI flow of infarction related artery in patients with AMI, occurrence of adverse cardiac events was the same as those in control group. Key words: Acute myocardial infarction;  Percutaneous coronary intervention;  Safety;  Efficacy